BlackRock, Inc. 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-27 4:12 pm Purchase | 2026-03-31 | 13G | CORVUS PHARMACEUTICALS INC CRVS | BlackRock, Inc. BLK | 5,387,818 6.400% | 1,372,308 (+34.18%) | Filing |
| 2025-10-17 6:40 pm Purchase | 2025-09-30 | 13G | CORVUS PHARMACEUTICALS INC CRVS | BlackRock, Inc. BLK | 4,015,510 5.400% | 4,015,510 (New Position) | Filing |